The vast amount of real-world data collected during routine clinical care is a treasure trove of safety information – but there are challenges to overcome before this rich source of evidence can be applied to pharmacovigilance. Patrick Ryan from Johnson & Johnson discusses how to harness real-world data for patient safety. Tune in to find out: How real-world data is collected and analysedWhich pharmacovigilance processes will benefit most from itHow to make data accessible without infringing patient privacy  Want to know more? Review the basics of real-world data and its use in the medicines life cycle in Pharmaceutical Medicine, or read up on the opportunities and challenges for pharmacovigilance in Clinical Pharmacology & Therapeutics. In partnership with the Observational Health Data Sciences and Informatics (OHDSI) and the European Health Data & Evidence Network (EHDEN) consortia, UMC researchers are exploring how real-world data can help prioritise and validate signals in pharmacovigilance. Read about their latest collaboration on Uppsala Reports. Another important player in the real-world data space is the Data Analysis and Real World Interrogation Network (DARWIN), which aims to provide timely and reliable evidence from real-world healthcare databases in the EU to improve the safety and effectiveness of medicines. For more on evidence in pharmacovigilance, don’t miss this interview with Daniele Sartori on spontaneous reporting or this conversation with Elena Rocca on uncertain evidence and big data. You can hear more about working with real-world data from the EHDEN network partners on the Voice of EHDEN podcast. Join the conversation on social media Follow us on Twitter, Facebook or LinkedIn and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.